135637-46-6 Usage
Uses
Different sources of media describe the Uses of 135637-46-6 differently. You can refer to the following data:
1. Phosphodiesterases (PDE) enzymatically convert the cyclic nucleotide second messengers cAMP and cGMP to 5’-AMP and 5’-GMP, respectively, thus terminating signal transduction. The cAMP-specific PDE4 isoforms may be particularly important in certain respiratory and neurological diseases. CP 80,633 is a selective inhibitor of PDE4 (IC50 = 1.27 μM for PDE4 versus. >100 μM for PDE1, PDE2, PDE3, and PDE5). It potentiates PGE1-dependent increases in cAMP levels in eosinophils, monocytes, and T-cells, inhibits eosinophil superoxide production (IC50 < 0.6 μM), and blocks LPS-induced TNF-α release from monocytes (IC50 = 0.22 μM). CP 80,633 (1 mg/kg) significantly reduces antigen-induced airway inflammation in atopic guinea pigs, monkeys, and mice.[Cayman Chemical]
2. CP 80633 is a selective inhibitor of phosphodiesterase type 4.
Biological Activity
Selective inhibitor of phosphodiesterase type 4 (IC 50 values are 1.9, > 100, > 100, > 100 and > 100 μ M for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells.? Displays anti-inflammatory and bronchodilatory effects in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 135637-46-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,6,3 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 135637-46:
(8*1)+(7*3)+(6*5)+(5*6)+(4*3)+(3*7)+(2*4)+(1*6)=136
136 % 10 = 6
So 135637-46-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H24N2O3/c1-22-15-5-4-12(14-9-19-18(21)20-10-14)8-17(15)23-16-7-11-2-3-13(16)6-11/h4-5,8,11,13-14,16H,2-3,6-7,9-10H2,1H3,(H2,19,20,21)/t11-,13+,16+/m1/s1
135637-46-6Relevant articles and documents
Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one
-
Page column 19, (2008/06/13)
This invention relates to novel processes for preparing the pharmaceutically active compound 5-(3-[(2S)-exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one and its corresponding 2R enantiomer and for preparing certain in
